RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Beijing’s BeiGene will receive a $150 million termination payment from Celgene because Celgene will end its $1.4 billion partnership for ex-China rights to BeiGene’s PD-1 candidate. The original deal included a provision that BeiGene’s tislelizumab would be Celgene’s only PD-1 project. Once Celgene agreed to be acquired by Bristol-Myers Squibb, tislelizumab was in jeopardy, given BMS’s very successful anti-PD-1 antibody, Opdivo. In 2017, Celgene paid $263 million upfront for ex-China rights to tislelizumab.
Source: China Biotoday
